Extranodal Lymphoma

hematologic malignancy

Identifier: CI-CAN-00002653
Entity page: /cancer/extranodal-lymphoma ↗
Edges: 347

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Extranodal Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 84show all (up to 200)
→ investigated in trials for	Rituximabmonoclonal antibody 36 trials (4 active) · roll-up of the cancer and its descendants	—	—	Extranodal Lymphoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule

Extranodal Lymphoma studied in …STUDIED_INderived10 of 263show all (up to 200)
→ studied in	NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 263 trials mapped (53 active)	—	—	Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04414163Phase 2 · active not recruiting A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	1	Observed	clinicaltrials	graph →
→ studied in	NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	1	Observed	clinicaltrials	graph →
→ studied in	NCT07791615Phase 2 · not yet recruiting A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma · condition mapped PROBABILISTIC · 263 trials mapped (53 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00336063Phase 1 · active not recruiting Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 263 trials mapped (53 active)	—	—	Adult Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07768943Phase 2 · not yet recruiting GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07678229Phase 3 · recruiting BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL · condition mapped ALIAS · 263 trials mapped (53 active)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains